Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature
Eirini Thanopoulou(Cancer Research Institute), Valentina Guarneri(Istituto Oncologico Veneto), Morena Caira(Università Cattolica del Sacro Cuore), Patrick Neven(KU Leuven), Andrew Wardley(UK Research and Innovation), Leila Khader(Eli Lilly (Italy)), Johannes Ettl(TUM Klinikum), Federica Miglietta(University of Padua)
Cited by 35
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k